activistprofile
JANA Partners Management, LP
I. Basics
JANA Partners, founded in 2001 by Barry Rosenstein, is an activist investment firm focused on leveraging shareholder engagement
activistprofile
Engaged Capital LLC
I. Basics
Engaged Capital, LLC, ("Engaged Capital") was established in 2012 by a group of professionals with significant
activistletters
Galloway Capital Threatens Legal Action Against Weight Watchers (WGHTQ) Over Bankruptcy Plan That Wipes Out Shareholders
Summary
On July 2025, Galloway Capital Partners announced it is considering legal action against WW International (OTCPK: WGHTQ), its board,
activistletters
Sherwood Group Slams Barnwell Industries (BRN) for Governance Failures and Ongoing Losses, Urges Shareholder Support for Board Overhaul
Summary
On May 19, 2025, the Sherwood Group, which owns ~29.9% of Barnwell Industries, issued a letter condemning the
activistletters
Sherwood Group Rallies Barnwell Industries (BRN) Shareholders, Claims Strong Support for Board Overhaul Ahead of Annual Meeting
Summary
On May 19, 2025, the Sherwood Group, holding ~29.9% of Barnwell Industries, announced strong early support for its
activistletters
Mason Capital Urges SEC Probe into ISS, Glass Lewis Recommendations on JBS (JBSS3.SA) U.S. Listing Proposal
Summary
On May 15, 2025, Mason Capital, a 2.4% minority shareholder in JBS S.A., sent a letter to
activistletters
HG Vora Calls for Overhaul at PENN Entertainment (PENN), Citing Years of Underperformance and Board Entrenchment
Summary
HG Vora, a 4.8% shareholder in PENN Entertainment, criticized the company’s long-term underperformance, failed digital strategy, and
activistletters
H Partners Urges Shareholders to Withhold Votes at Harley-Davidson (HOG) Annual Meeting, Targeting CEO Zeitz and Longtime Directors for Value Destruction
Summary
H Partners urged shareholders to vote “WITHHOLD” on the re-election of CEO/Chairman Jochen Zeitz, Presiding Director Thomas Linebarger,
activistletters
ADAR1 Capital Slams Keros Therapeutics (KROS) Strategy, Urges Board Overhaul and Cash Return Amid Pipeline Concerns
Summary
ADAR1 Capital, owning 13.3% of Keros Therapeutics, criticized the company’s strategy, citing poor clinical results for two
activistletters
BML Capital Urges AN2 Therapeutics (ANTX) to Pursue Sale or Liquidation After Phase 3 Failure, Threatens Withhold Vote at Annual Meeting
Summary
BML Capital, owning 19.1% of AN2 Therapeutics, urged the Board to pursue a sale or orderly wind-down of